Given that the average IC50 values of the drugs targeting TYMS (e.g. Methotrexate), which are already approved chemotherapy drugs for breast cancer [38], were 64.155\documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{upgreek}\usepackage{mathrsfs}\setlength{\oddsidemargin}{-69pt}\begin{document}$\mathrm{\mu}$\end{document}M in 50 breast cancer cell-line samples, these results highlights that the drugs targeting KIF11 and AURKA also could be effective individualized chemotherapy drugs for breast cancer. This evidence concerns the gene TYMS and breast carcinoma.